NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune Inc.
Phase 2 Terminated
Clinical Trials
77 trialsNCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT02982694 2025-10-01
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Vall d'Hebron Institute of Oncology
Phase 2 Terminated
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT04952753 2025-03-26
daNIS-3
Novartis
Phase 2 Terminated
NCT05717400 2024-12-31
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05824559 2024-11-21
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
MEI Pharma, Inc.
Phase 1 Terminated
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT00601198 2023-08-01
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Phase 2 Terminated
NCT00303628 2023-07-06
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Terminated
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03176264 2021-10-12
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
Novartis
Phase 1 Terminated
NCT00314353 2021-10-06
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NSABP Foundation Inc
Phase 2 Terminated
NCT02015923 2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4 Terminated
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT00602329 2020-04-28
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02141295 2020-03-25
McCAVE
Hoffmann-La Roche
Phase 2 Terminated
NCT00544700 2020-02-20
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Swiss Cancer Institute
Phase 3 Terminated
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT01532804 2019-12-26
BEVATOMOX
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Terminated
NCT03382886 2019-12-12
NUANCE
University of Utah
Phase 1 Terminated
NCT02654639 2018-08-07
ALEXANDRIA
Georgetown University
Phase 2 Terminated
NCT00642603 2018-03-29
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01765582 2017-09-18
STEAM
Hoffmann-La Roche
Phase 2 Terminated
NCT00324987 2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00449163 2017-05-11
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
University of Miami
Phase 2 Terminated
NCT00127036 2017-03-23
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated